Tomatoes Recalled After FDA Warns of Severe Health Riskt
Before you throw some tomatoes on your sandwich this week, think again. On June 1, The New York Times announced that the FDA escalated a tomato recall to a high warning due to a threat of severe illness and even death.
The outlet added that the hazardous bacteria found on select tomatoes in three southern states "can survive for weeks in dry environments and months in wet ones." The infected tomatoes were distributed between April 23 and 28 in Georgia, North Carolina, and South Carolina by the H&C Farms Label.
At this time, the source of contamination is unknown. The NYT writes, "Exposure to salmonella, a bacteria, can be deadly, especially in adults over 65, children under 5 and people with compromised immune systems, who have the highest risk of severe illness."
Salmonella contamination causes symptoms that range from diarrhea, abdominal cramps, and fever within 8 to 72 hours after exposure, per Mayo Clinic.
This update comes amid a wave of other product recalls. On May 29, Newsweek reported that a food company in Georgia has issued a voluntary recall on "hundreds of thousands of pounds of canned beef stew products due to potential foreign material contamination."
In total, 256,185 pounds of Dinty Moore Beef Stew were recalled. Per the outlet, the recall included 20-oz cans of the product marked with a "best by" date of February 2028.
"The problem was identified after Hormel Foods Corporation notified the FSIS of three consumer complaints reporting pieces of wood in the beef stew."
In a statement, Hormel Foods Corporation told Newsweek that "no other Dinty Moore products are affected, and no illnesses or injuries have been reported in association with this recall."Tomatoes Recalled After FDA Warns of Severe Health Riskt first appeared on Men's Journal on Jun 1, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNET
34 minutes ago
- CNET
The FDA Warns of New Zyrtec and Xyzal Side Effect. What Is Pruritus?
According to the FDA, 62.7 million over-the-counter packages of Zyrtec (cetirizine) and Xyzal (levocetirizine) were purchased in 2022. Since allergies are getting worse -- partly because of climate change creating longer, more intense pollen seasons -- these numbers have likely climbed in the last three years as more people purchase the antihistamines to cope with allergy symptoms like a stuffy nose, watery, red, itchy eyes and hives. For the millions of people who take these drugs, it's important to know that the FDA recently published a warning about a newly discovered side effect that may occur after taking both Zyrtec and Xyzal. If you stop taking Zyrtec or Xyzal after long-term use, you might experience "rare but severe" itching. Also called pruritus, this itching was experienced by patients who had been taking these allergy medicines every day for several months or years and then stopped. What is the FDA going to do? The FDA decided to issue this warning after identifying 209 cases worldwide -- 180 cases for cetirizine, 27 for levocetirizine and two for both -- of this particular side effect reported between April 2017 and July 2023. In the US, 197 cases were reported. However, there may be more, because these are only those that were reported to the FDA. Interestingly, even though most patients who experienced this severe itching had been taking these antihistamines for more than three months, some had this reaction after less than one month of use. Because of these findings, the FDA will now include a warning on the prescribing information for prescription cetirizine and levocetirizine. The administration is also asking that manufacturers add this warning to drug facts labels for OTC versions. When to contact your doctor If you stop taking OTC cetirizine or levocetirizine and develop severe itching within a few days after you've been using the medicine daily for several months to years, you should contact your doctor. If you plan to take these medicines for a prolonged period of time, you should also discuss the pros and cons with your doctor before starting. How to treat this new Zyrtec and Xyzal side effect According to the FDA, no effective treatments for pruritus have been found. However, most patients discovered that their symptoms resolved after they restarted cetirizine or levocetirizine or after they tapered off the antihistamine after restarting it. Before you try this, consult your doctor to make sure that's the best course of action if you think you're dealing with this Zyrtec or Xyzal complication. According to the FDA, the most common, already-known side effects of cetirizine and levocetirizine are fatigue, drowsiness, sore throat, cough, dry mouth, nosebleed, fever, diarrhea and vomiting. What is pruritus? Plus, additional symptoms to know The Cleveland Clinic reports that pruritus is the medical term for "itchiness." It can be painful or irritating and spread to multiple areas of the body. Other symptoms of pruritus can include a rash, blisters, large bumps, small pimple-like bumps and skin discoloration. Scratching the skin can cause additional symptoms, such as skin breaks and bleeds, scratch marks, dry or cracked skin, broken skin that leaks a yellow to white fluid (infection), localized pain where the skin itches and a thick, leathery patch. That is why it's important to do what you can to manage your itching under the care of a doctor. Dry skin, pregnancy, contact with an allergen and a reaction medication are common causes of pruritus. If it occurs for over six weeks, it can be considered chronic.


Business Wire
an hour ago
- Business Wire
FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide for more effective treatment or diagnosis of life-threatening diseases, such as cancer, than current options. The goal of the FDA's Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review. 'Every late-stage cancer we avert is a win for patients and for the entire healthcare system,' said AmirAli Talasaz, Guardant Health co-founder and co-CEO. 'This recognition by the FDA shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw. We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly.' The Breakthrough Device designation by the FDA of the Shield MCD test builds on its recent selection by the National Cancer Institute (NCI) for the Vanguard Study evaluating emerging MCD technology. The Shield MCD test was chosen for the Vanguard study based on its strong performance in predicting the presence of cancers and cancer tissue of origin. At the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Guardant presented data on the clinical validation of the Shield MCD test showing that the blood-based test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy across multiple tumor types. The data presented from a case-control cohort showed that the Shield MCD test has 98.6% specificity and 75% cancer sensitivity across bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancers (per-cancer sensitivity range: 62-96%). Primary or secondary CSO (cancer signal origin) accuracy was 92%. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Yahoo
an hour ago
- Yahoo
FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test
PALO ALTO, Calif., June 03, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide for more effective treatment or diagnosis of life-threatening diseases, such as cancer, than current options. The goal of the FDA's Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review. "Every late-stage cancer we avert is a win for patients and for the entire healthcare system," said AmirAli Talasaz, Guardant Health co-founder and co-CEO. "This recognition by the FDA shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw. We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly." The Breakthrough Device designation by the FDA of the Shield MCD test builds on its recent selection by the National Cancer Institute (NCI) for the Vanguard Study evaluating emerging MCD technology. The Shield MCD test was chosen for the Vanguard study based on its strong performance in predicting the presence of cancers and cancer tissue of origin. At the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Guardant presented data on the clinical validation of the Shield MCD test showing that the blood-based test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy across multiple tumor types. The data presented from a case-control cohort showed that the Shield MCD test has 98.6% specificity and 75% cancer sensitivity across bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancers (per-cancer sensitivity range: 62-96%). Primary or secondary CSO (cancer signal origin) accuracy was 92%. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Meaghan Smithpress@ Sign in to access your portfolio